Cargando…
Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
D17DT consists of the GnRH decapeptide linked to diphtheria toxoid. The aim of this pilot study was to assess the tolerance of D17DT and the production of anti-GnRH antibodies from two doses, 30 and 100 μg, in patients with locally advanced prostate cancer. Twelve patients with histologically proven...
Autores principales: | Simms, M S, Scholfield, D P, Jacobs, E, Michaeli, D, Broome, P, Humphreys, J E, Bishop, M C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374644/ https://www.ncbi.nlm.nih.gov/pubmed/10945488 http://dx.doi.org/10.1054/bjoc.2000.1315 |
Ejemplares similares
-
Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study
por: Mytilekas, Vaios-Konstantinos, et al.
Publicado: (2023) -
Comparison of GnRH agonist versus luteal estradiol
GnRH antagonist protocol using transdermal testosterone in poor
responders
por: Fàbregues, Francesc, et al.
Publicado: (2019) -
Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding
por: Flanagan, Colleen A., et al.
Publicado: (2017) -
The role of GnRH metabolite, GnRH-(1-5), in endometrial cancer
por: Cho-Clark, Madelaine J., et al.
Publicado: (2023) -
GnRH-immunocastration: an alternative method for male animal surgical castration
por: Wang, Chun, et al.
Publicado: (2023)